Jinming Zhou | Medicinal Chemistry | Best Researcher Award Posted on 09/11/202409/11/2024 by sciencefatherLeave a Comment on Jinming Zhou | Medicinal Chemistry | Best Researcher Award Dr. Jinming Zhou | Medicinal Chemistry| Best Researcher Award Research and Grant Success: Dr. Zhou’s research has been consistently supported by prestigious National Natural Science Foundation (NCSF) grants, with four approvals to date. This grant success not only reflects the high quality and impact of his research but also indicates his capacity to conduct rigorous and relevant studies that address critical health challenges. Dr. Jinming Zhou, Zhejiang Normal University , China Profile Scopus OrcID 🌱EARLY ACADEMIC PURSUITS Dr. Zhou’s academic journey began at Beijing Normal University, where he earned his Bachelor of Science (B.S.) in 2000 and Master of Science (M.S.) in 2003. His passion for rational drug design led him to pursue a Ph.D. at the Shanghai Institute of Organic Chemistry, where he specialized in this field, establishing a strong foundation in medicinal chemistry. Postdoctoral training followed at McGill University in Canada, where he continued advancing in rational drug design and gained international research exposure. 💼 PROFESSIONAL ENDEAVORS In 2010, Dr. Zhou joined the Institute of Medicinal Biotechnology at the Chinese Academy of Medical Science as an Associate Professor. Demonstrating outstanding contributions in drug research, he achieved full professorship in 2017. His career took a new turn in 2018 when he accepted a professorship at Zhejiang Normal University, where he also became the Director of the Drug Development and Innovation Center. Dr. Zhou’s leadership at this center has been pivotal in establishing innovative practices and groundbreaking projects. 🔬CONTRIBUTIONS AND RESEARCH FOCUS Dr. Zhou’s research team is at the forefront of developing anti-viral and anti-cancer drugs. His group combines rational drug design and applied medicinal research to create effective therapeutic solutions. His work has a special emphasis on translational medicine, aiming to bridge scientific research and clinical applications. He has secured four prestigious National Natural Science Foundation (NCSF) grants, supporting his work in advancing therapeutic drug development. 📚ACADEMIC CITES With over a hundred publications, Dr. Zhou has significantly impacted medicinal chemistry, particularly in antiviral and anticancer drug design. His research has become a widely cited reference in related studies, underscoring his scientific contributions’ value and relevance. 🌍IMPACT AND INFLUENCE Dr. Zhou’s influence in the medicinal chemistry field is highlighted by his 100+ publications in high-impact journals, showcasing the scientific community’s recognition of his expertise. His achievements were honored in 2012 with the prestigious “Xiehe Star” award, recognizing his exceptional contributions to the field of drug design. 🌟LEGACY AND FUTURE AND CONTRIBUTIONS As Dr. Zhou continues his work at the Drug Development and Innovation Center, he is shaping a new generation of researchers focused on tackling global health challenges. His legacy is built not only on his published works but also on his mentorship and role in expanding the field of drug innovation. His ongoing research promises to further the understanding of rational drug design and its applications in combating complex diseases. 📄Publications “Inducing or enhancing protein-protein interaction to develop drugs: Molecular glues with various biological activity” Authors: Zhang, R., Zheng, Y., Xiang, F., Zhou, J. Journal: European Journal of Medicinal Chemistry, 2024, 277, 116756 “METTL3 inhibitor suppresses the progression of prostate cancer via IGFBP3/AKT pathway and synergizes with PARP inhibitor” Authors: Chen, X., Wang, M., Wang, H., Zhou, J., Wu, M. Journal: Biomedicine and Pharmacotherapy, 2024, 179, 117366 “Autophagy mediated targeting degradation, a promising strategy in drug development” Authors: Zhang, J., Pan, X., Ji, W., Zhou, J. Journal: Bioorganic Chemistry, 2024, 149, 107466 “A novel hydrophobic tag leads to the efficient degradation of programmed death-ligand 1” Authors: Gao, J., Xie, Y., Zhang, J., Cen, S., Zhou, J. Journal: RSC Medicinal Chemistry, 2024, 15(9), pp. 3038–3047 “Design and Synthesis of Dual-Target Inhibitors Targeting Androgen Receptors and Glucocorticoid Receptors to Overcome Antiandrogen Resistance in Castration-Resistant Prostate Cancer” Authors: Li, C., Han, X., Yan, Q., Wu, M., Zhou, J. Journal: Journal of Medicinal Chemistry, 2024, 67(5), pp. 3419–3436
Shan Su | Oncology | Best Researcher Award Posted on 08/11/202411/11/2024 by sciencefatherLeave a Comment on Shan Su | Oncology | Best Researcher Award Dr. Shan Su | Oncology | Best Researcher Award Professional Memberships: Her membership with the International Association for the Study of Lung Cancer (IASLC) indicates her active participation in the global oncology research community, further enhancing her profile as a top researcher. Dr. Shan Su ,Guangzhou Chest Hospital, China Profile Scopus OrcID 🌱EARLY ACADEMIC PURSUITS Shan Su began her academic journey with a strong focus on clinical oncology, immersing herself in the study of treatment methodologies and therapies for various types of cancer, especially lung cancer. Early in her career, her dedication to patient-centered treatment approaches led her to explore a range of therapeutic practices, including chemotherapy, targeted therapies, and immunotherapy. 💼 PROFESSIONAL ENDEAVORS As the Chief Physician at Guangzhou Chest Hospital, Shan Su has taken on a prominent role in the field of oncology, specializing in advanced and innovative cancer treatments. Over her ten-year tenure, she has applied targeted therapy, immunotherapy, and even local microwave ablation to treat malignant tumors, focusing particularly on lung tumors. Her role involves not only treating patients but also leading clinical advancements and educating the next generation of oncology professionals. 🔬CONTRIBUTIONS AND RESEARCH FOCUS Dr. Su’s research has paved the way in studying complex interactions between malignancies and other diseases, notably tuberculosis (TB). Recognizing a gap in the understanding of cancer patients with concurrent TB, she led a pioneering cohort study—the largest of its kind worldwide—documenting unique treatment challenges and outcomes. Currently, she is spearheading the first international clinical study investigating the effects of combining first-line chemotherapy with immunotherapy for lung cancer patients who have active pulmonary TB, with a primary focus on evaluating the safety and efficacy of these combined treatments. 📚ACADEMIC CITES Throughout her career, Dr. Su’s research has been recognized and cited by numerous peers in the medical community, underscoring her contributions to oncology and her influence on cancer research. Her work in combining immunotherapy with chemotherapy for complex cases is particularly well-regarded, with citations reflecting the growing interest and importance of her findings. 🌍IMPACT AND INFLUENCE Dr. Su’s work has influenced clinical practices on a global scale. Her expertise has contributed significantly to the understanding of complex cases involving co-occurring cancer and TB, impacting treatment protocols and inspiring other researchers to explore similar areas. As a member of the International Association for the Study of Lung Cancer (IASLC), she collaborates with a network of global oncology professionals to advance knowledge and share insights into lung cancer treatment. 🌟LEGACY AND FUTURE AND CONTRIBUTIONS Looking forward, Dr. Su remains committed to advancing oncological treatments, especially for complex cases like cancer with tuberculosis. Her ongoing research projects hold great promise for improving patient outcomes and expanding treatment options, making her a pioneer in her field. Dr. Su’s legacy will likely include groundbreaking contributions to cancer therapy innovations, laying the foundation for future treatments and offering hope for patients worldwide. 📄Publications The Efficacy and Safety of Anlotinib Alone and in Combination with Other Drugs in Advanced Lung Cancer: A Retrospective Cohort Study Authors: Li, L., Zhang, H., Xie, Y., Cen, W., Koundal, D. Journal: Computational and Mathematical Methods in Medicine, 2022, 2022, 1475871 Assessment of anti-PD-(L)1 for patients with coexisting malignant tumor and tuberculosis classified by active, latent, and obsolete stage Authors: Su, S., Ye, M.-F., Cai, X.-T., Huang, H.-Y., Dong, Z.-Y. Journal: BMC Medicine, 2021, 19(1), 322 Construction of a Prognostic Immune Signature for Squamous-Cell Lung Cancer to Predict Survival Authors: Chen, R.-L., Zhou, J.-X., Cao, Y., Wang, S.-Y., Lin, L.-Z. Journal: Frontiers in Immunology, 2020, 11, 1933 Tumor Mutational Burden and Genomic Alterations in Chinese Small Cell Lung Cancer Measured by Whole-Exome Sequencing Authors: Su, S., Zou, J.-J., Zeng, Y.-Y., Zhao, Z.-G., Liu, J.-X. Journal: BioMed Research International, 2019, 2019, 6096350 Hyaluronic acid-modified selenium nanoparticles for enhancing the therapeutic efficacy of paclitaxel in lung cancer therapy Authors: Zou, J., Su, S., Chen, Z., Xia, Y., Huang, D. Journal: Artificial Cells, Nanomedicine and Biotechnology, 2019, 47(1), pp. 3456–3464